Immuneering Corporation
IMRX
$5.95
$0.030.51%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.98% | -2.68% | -15.76% | 3.74% | 5.18% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.04% | 1.04% | 13.84% | 9.68% | 10.43% |
| Operating Income | 1.04% | -1.04% | -13.84% | -9.68% | -10.43% |
| Income Before Tax | -2.51% | -5.16% | -19.68% | -15.90% | -15.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.51% | -5.16% | -19.68% | -15.90% | -15.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.51% | -5.16% | -19.68% | -15.90% | -15.52% |
| EBIT | 1.04% | -1.04% | -13.84% | -9.68% | -10.43% |
| EBITDA | 1.01% | -1.08% | -13.95% | -9.66% | -10.41% |
| EPS Basic | 15.52% | 13.07% | -12.83% | -13.66% | -11.59% |
| Normalized Basic EPS | 15.53% | 14.03% | -12.79% | -10.50% | -11.62% |
| EPS Diluted | 15.52% | 13.07% | -12.83% | -13.66% | -11.59% |
| Normalized Diluted EPS | 15.53% | 14.03% | -12.79% | -10.50% | -11.62% |
| Average Basic Shares Outstanding | 21.36% | 20.97% | 6.08% | 1.97% | 3.51% |
| Average Diluted Shares Outstanding | 21.36% | 20.97% | 6.08% | 1.97% | 3.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |